Progress in adjuvant chemotherapy for breast cancer: an overview

Table 2 Classification of adjuvant chemotherapy regimens

Generation*	Benefit	Regimens with substantial evidence base
First	35 % reduction in breast cancer mortality compared with no adjuvant chemotherapy	CMFx6, ACx4, FEC50x6
Second	20 % reduction in breast cancer mortality compared with first generation regimen	FEC100x6, CAFx6, FACx6
		ACx4-Tx4 (q3wks)
		DCx4, Ex4-CMFx4
Third	20 % reduction in breast cancer mortality compared with second generation regimen	FECx4-Dx3, FECx4-weekly Tx8
		Concurrent DAC
		Dose-dense ACx4-Tx4
		ACx4-weekly paclitaxel
		ACx4-docetaxel (q 3 weeks)

*Adopted from Adjuvant online with modifications [50, 51]
CMF, Cyclophosphamide, methotrexate, 5-flourouracil; AC, Doxorubicin, cyclophosphamide; FEC50, 5-flourouracil, epirubicin (50 mg/m²), cyclophosphamide; FEC100, 5-flourouracil, epirubicin (100 mg/m²), cyclophosphamide; DC, Docetaxel, cyclophosphamide; CAF, Cyclophosphamide, doxorubicin, 5-flourouracil; FAC, 5-flouroracil, doxorubicin, cyclophosphamide; DAC, Docetaxel, doxorubicin, cyclophosphamide; T, paclitaxel; D, Docetaxel; E, Epirubicin

ISSN: 1741-7015